Overview

Open Label Prostate Cancer Study

Status:
Completed

Trial end date:
2015-10-01

Target enrollment:

Participant gender:

Summary

The main purpose of the study is to investigate the safety and tolerability of AZD3514 when given orally to patients with castration-resistant prostate cancer (CRPC)

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca